AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 32 min read$MIST

Milestone Wins NMPA Approval For Etripamil Nasal Spray In PSVT

Milestone Pharmaceuticals (MIST) received NMPA approval for its Etripamil nasal spray to treat PSVT in China. The approval, based on Phase 3 study data, is the first outside the U.S. and could yield up to $98M in milestones. MIST stock is up 5% at $1.23.

Original reporting
rttnews.com
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 4:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$MIST
Bullish
high confidence
Mentioned
$MIST
Relevance
9/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$MISTBullishHigh
01

Why it matters

The approval unlocks a large patient population in China and triggers up‑to $98 million in milestone payments, likely supporting near‑term share price appreciation.

02

Market read

Regulatory approval is a catalyst for Milestone and may influence other cardiac‑therapy biotech stocks.

03

What to watch

Potential reimbursement challenges in China and the need for further data to support broader adoption.

Relevance 9/10Novelty 9/10Timing: today

Background

Milestone Pharmaceuticals (NASDAQ:MIST) announced its first non‑US regulatory clearance for the Etripamil nasal spray, targeting paroxysmal supraventricular tachycardia.

Company-level read

Ticker impact

$MISTBullishHigh confidence
Context

Milestone Pharmaceuticals received NMPA approval for its Etripamil nasal spray, the first regulatory clearance outside the United States.

Expected impact

Potential upside as the stock may rally on the approval and upcoming commercial launch.

Evidence & confidence

Approval is a primary, material event for a biotech; the company also announced up‑to $98 million in milestone payments, which can materially boost cash flow.

Market effects

Sector

Adds a new approved therapy to the cardiac arrhythmia space, potentially pressuring peers without Chinese approvals.

Regional

Strengthens the biotech segment in Greater China and may boost related Chinese pharma stocks.

Global

Demonstrates successful US‑China regulatory navigation, relevant for other US‑listed biotech firms seeking foreign approvals.

Counterpoint

What could challenge this read

The market may have already priced in the approval; execution risk in China could limit upside.

Key entities

  • company
    Milestone Pharmaceuticals Inc.

    US‑listed biotech developing Etripamil.

  • partner
    Everest Medicines

    Exclusive licensee for commercialization in Greater China.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 9
$MISTMed

Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial

Milestone Pharmaceuticals (MIST) announced the first European patient has been enrolled in its Phase 3 ReVeRA-301 trial for etripamil nasal spray to treat atrial fibrillation with rapid ventricular rate (AFib-RVR). The study, targeting 150 patients, is evaluating the same 70 mg dose approved for PSVT in the U.S. as CARDAMYST. Enrollment is ongoing in the U.S. and Canada.

globenewswire.com2 min
SEP 24
$MISTMedAI 8/10

Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR

Milestone Pharmaceuticals (MIST) announced the first Canadian patient enrollment in the ReVeRA-301 Phase 3 trial for etripamil nasal spray, targeting atrial fibrillation with rapid ventricular rate (AFib-RVR). The study aims to enroll 150 patients globally, evaluating the 70 mg dose already FDA-approved for PSVT as CARDAMYST.

finanznachrichten.de2 min
SEP 4
$IONSHighAI 9/10

Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals

Ionis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.

rttnews.com3 min
SEP 3
$MISTHighAI 8/10

Milestone Gets China Approval For Etripamil Nasal Spray

Milestone Pharmaceuticals (MIST) announced China's approval of etripamil nasal spray for treating PSVT in adults, triggering a $2M milestone payment. Everest Medicines holds exclusive rights in Greater China, with up to $98M in potential milestones and 18% royalties. The approval was based on Phase 3 study data showing significant efficacy over placebo.

rttnews.com2 min